714,890 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Phocas Financial Corp.

Phocas Financial Corp. bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 714,890 shares of the company's stock, valued at approximately $4,339,000. Phocas Financial Corp. owned 0.23% of Amneal Pharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. increased its holdings in shares of Amneal Pharmaceuticals by 43.2% during the first quarter. American Century Companies Inc. now owns 21,715 shares of the company's stock worth $30,000 after purchasing an additional 6,549 shares during the period. Engineers Gate Manager LP bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at approximately $34,000. Tower Research Capital LLC TRC increased its stake in Amneal Pharmaceuticals by 120.0% in the second quarter. Tower Research Capital LLC TRC now owns 11,165 shares of the company's stock valued at $35,000 after acquiring an additional 6,089 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Amneal Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Amneal Pharmaceuticals in the second quarter valued at approximately $38,000. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Down 3.0 %

Shares of NASDAQ AMRX traded down $0.17 during trading on Friday, hitting $5.52. 2,184,811 shares of the company traded hands, compared to its average volume of 1,694,057. The business's fifty day moving average is $5.73 and its 200 day moving average is $5.11. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $1.33 and a fifty-two week high of $6.46. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -17.81 and a beta of 1.33. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.94 and a current ratio of 1.63.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.05 by $0.07. The company had revenue of $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of research reports. StockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, March 4th. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an "overweight" rating in a report on Monday, January 29th. The Goldman Sachs Group boosted their target price on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a "buy" rating in a report on Monday, March 4th. Finally, Piper Sandler boosted their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an "overweight" rating in a report on Thursday, March 21st. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $7.31.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.